Daily Bulletin

Men's Weekly

.

Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

TOULOUSE, France, Nov. 9, 2020 /PRNewswire/ -- Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams. The study...

Read more: Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody...

More Articles ...

  1. OrbusNeich® Medical and P+F Products & Features® announce new partnership-PR Newswire APAC
  2. The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start
  3. Global Beauty & Wellness Awards announces Best Cosmetics and Hotels in the World 2020-PR Newswire APAC
  4. Centennial Property Group Announces Offering of AUD$100Million Senior Secured Loan Note Program-PR Newswire APAC
  5. Amcor reports strong first quarter results and raises outlook for fiscal 2021-PR Newswire APAC
  6. Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy
  7. New football simulator Football for Friendship World to be released on World Football Day
  8. FP Markets recognised as 'Best FX Broker Australia' for 2020
  9. Cellarity signs up with Excelra for GOSTAR database to enrich its drug discovery platform-PR Newswire APAC
  10. Cloud4C and SNP Ink Global Partnership Agreement-PR Newswire APAC

Business News

Strategic partnerships to enable global acceleration for Aussie fashion brands: SHEIN Xcelerator launches

SHEIN Xcelerator is introducing a more agile, demand-led operating model, allowing brands to scale while retaining control over creative direction and identity. For fashion brands, the pressure t...

Daily Bulletin - avatar Daily Bulletin

Tips for Avoiding Probate Delays

Probate can be a lengthy process at the best of times, and delays often compound the stress that comes with managing a loved one's estate. Many of those delays are avoidable with the right preparati...

Daily Bulletin - avatar Daily Bulletin

Integrating Marketing Automation Workflows with Headless CMS: Creating a Unified Engine for Scalable Growth

Marketing automation is a necessary component of modern engagement with customers. Automated emails, triggered campaigns, lead nurturing and lifecycle messaging enable brands to scale their messagin...

Daily Bulletin - avatar Daily Bulletin